期刊文献+

左炔诺孕酮宫内缓释系统治疗功能失调性子宫出血的临床观察 被引量:21

The role of levonorgestrol-releasing intrauterine system in the treatment of dyfunctional uterine bleeding.
下载PDF
导出
摘要 目的:观察左炔诺孕酮宫内缓释系统(LNG-IUS)治疗功能失调性子宫出血的临床效果。方法:48例确诊为功能失调性子宫出血的患者,放置LNG-IUS。置宫内节育器前后均行宫腔镜检查、月经量评分、测量子宫内膜厚度;检测卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)和孕酮(P)浓度及子宫内膜雌、孕激素受体(ER/PR)。结果:置宫内节育器3个月后,月经量明显减少,PBAC法月经量评分由置宫内节育器前(128.9±41.5)降至(52.2±13.8),具有统计学意义(P<0.01);子宫内膜由(12.9±4.2)mm降至(8.4±2.0)mm,差异具有统计学意义(P<0.05)。置宫内节育器6个月后,宫腔镜下观察,子宫内膜菲薄,病理显示内膜呈轻度分泌现象及间质蜕膜样变;ER、PR的表达均显著下调(P<0.01)。结论:LNG-IUS能有效地减少月经量,对增生的子宫内膜具有逆转作用,治疗功能失调性子宫出血效果好。 Objective:To evaluate the effect of levonorgestrol-releasing intrauterine system ( LNG-IUS ) on the endometrium. Methods :48 patients with dysfunctional uterine bleeding were treated with LNG-IUS. The menstrual blood loss and the thickness of endometrium by color ultrasonography were observed and hysteroscopic examination was undertaken in pre- and post-insertion of LNG-IUS respectively. ER and PR expression in the endometrium with immunohistochemical method, serum-levels of FSH, LH, E2 and P were tested at 6 months after insertion. Results:Menstrual blood loss in the third month after insertion was decreased significantly and PBAC-score was changed from 128.9 ± 41.5 to 52.2 ± 13.8 (P 〈 0.01 ). At 6 months after application of LNG-IUS, hysteroscopic observation showed that the endometrium became thinner,and the thickness of endometrium by ultrasonographic examination was reduced from 12.9 ± 4.2mm to 8.4 ± 2.0mm ( P 〈 0.01 ). Pathological examination demonstrated that endometrial hyperplasia regressed and exhibited visible secretion and pseudeciducal reaction in all cases Expressions of ER fective therapy in and PR were down-regulated after treatment. Condusion:LNG-IUS is an ef- the treatment of endometfium hyperplasia. It strum blood loss and reverse the endometrium hyperplasia with can effectively reduce the menlittle effect on ovarian function.
出处 《现代妇产科进展》 CSCD 北大核心 2006年第10期753-756,F0003,共5页 Progress in Obstetrics and Gynecology
关键词 左炔诺孕酮 子宫内膜增生过长 药物释放系统 Levonorgestrel Endometrium hyperplasia Drug delivery system
  • 相关文献

参考文献10

  • 1Higham JM,OBrien PMS,Shaw RW.Assessment of menstrual blood loss using a pictorial chart[J].Br.J.Obstetr Gynecol,1990,97 (7):734
  • 2Huang A,Pettigrew NM,Waston PH.Immunphistochemical assay for oestrogen receptors in paraffin wax section of breast carcinoma using a new monoclonal antibody[J].J Pathol,1996,180:223-227
  • 3张莉嘉,翁梨驹.左炔诺孕酮宫内系统临床使用五年的安全性研究[J].中华妇产科杂志,2001,36(11):675-677. 被引量:113
  • 4Luukkainen T,Pakarinen P,Toivonen J.Progestin-releasing intrauterine systems[J].Semin Reprod Med,2001,19:355-363
  • 5Iao B,Wu SC,Chong J,et al.Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia[J].Fertil Steril,2003,79:963-969
  • 6Gardner FJE,Konje JC,Abrams KR,et al.Endometrial protection from tamoxifen-stimulatedchanges by a levonorgestrel-releasing intrauterine system a randomized controlled trial[J].The Lancet,2000,356:1711-1717
  • 7邓姗,郎景和.左炔诺孕酮宫内缓释系统的临床功用及相关基础研究[J].国外医学(妇产科学分册),2004,31(5):285-288. 被引量:148
  • 8I Cheng Chi,Farr G.The non-contraceptive effects of the levonorgestrel releasing intrauterine device:Adv[J].Contracept,1994,10:271-285
  • 9Bespoiasnaia W,Tumasian KP,Voronovskaia Ⅳ.Combined hormone therapy in hyperplasia of the endometrium[J].Lik Sprava,2000,9:49-52
  • 10Vereide AB,Kaino T,Sager G,et al.Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB),and estrogen receptors (ER-alpha and ER-beta)in human endometrial hyperplasia[J].Gynecol Oncol,2006,101 (2):214-223

二级参考文献23

  • 1Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum, 1998, 3(1): 11-14.
  • 2Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine system. Semi Reprod Med, 2001, 19(4): 355-363.
  • 3Zalel Y, Shulman A, Lidor A, et al. The local progestational efffect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study. Hum Reprod, 2002, 17(11):2878-2880.
  • 4Guillebaud .I. The levnorgestrel intrauterine systemL: a clinical perspective from the UK. Ann N Y Acad Sci, 2003, 997(2): 185-193.
  • 5Backman T, Huhtala S, Luoto R, et al. Advance information improves improves user satisfaction with the levonorgestrel intrauterine system.Obstet Gynecol, 2002, 99(4): 608-613.
  • 6French R, Cowan F, Mansour D, et al. Hormonally impregnated intrauterine systems(IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev, 2001,(2):CD001776.
  • 7Backman T, Rauramo I, Huhtala S, et al. Pregancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol, 2004, 190(1):50-54.
  • 8Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf, 2004, 27(2):75-90.
  • 9Xiao BL, Wu SC, Chong J, et al. Therapeutic effects of the lenonorgestrelrelesing intrauterina system in the treatment of idiopathic menorrhagia. Fertil Steril, 2003, 79(4):963-969.
  • 10Barrington JW, Arunkalivanan AS, Avdek-Fattah M. Compariso between the levonorgestrel intrauterine system (LNG-IUS)and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol, 2003, 108(1):72-74.

共引文献234

同被引文献128

引证文献21

二级引证文献138

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部